BPG is committed to discovery and dissemination of knowledge
Retrospective Study
Copyright: ©Author(s) 2026.
World J Gastroenterol. Jun 28, 2026; 32(24): 118757
Published online Jun 28, 2026. doi: 10.3748/wjg.118757
Table 5 Adverse events of grade 3 or 4 in the sarcopenic and non-sarcopenic patients, n (%)
Variable
Sarcopenic patients (n = 46)
Non-sarcopenic patients (n = 104)
P value
Total adverse events22 (47.8)28 (26.9)0.015
Hematologic toxicity16 (34.8)15 (14.4)0.001
Neutropenia15 (32.6)15 (14.4)
Anemia1 (2.2)0 (0.0)
Thrombocytopenia1 (2.2)0 (0.0)
Non-hematologic toxicity11 (23.9)13 (12.5)0.093
Nausea0 (0.0)1 (1.0)
Loss of appetite2 (4.3)1 (1.0)
Fatigue3 (6.5)0 (0.0)
Diarrhea0 (0.0)1 (1.0)
Skin rash5 (10.9)3 (2.9)
Peripheral neuropathy2 (4.3)8 (7.7)
Interstitial pneumonia3 (6.5)1 (1.0)


Write to the Help Desk